Cost effectiveness of a pharmacy-based coaching programme to improve adherence to antidepressants

PharmacoEconomics

Volumn 25, Issue 1, 2007, Pages 25-37

  Bosmans, Judith E ^a,e   Brook, Oscar H ^b   Van Hout, Hein P J ^c   De Bruijne, Martine C ^a   Nieuwenhuyse, Hugo ^b   Bouter, Lex M ^c   Stalman, Wim A B ^c   Van Tulder, Maurits W ^a,d  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b International Health Foundation   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d VU UNIVERSITY AMSTERDAM   (Netherlands)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DISEASE SEVERITY; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH PROGRAM; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT EDUCATION; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS;

EID: 33846106306     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200725010-00004     Document Type: Article

References (42)

1. Lepine JP, Gastpar M, Mendlewicz J, et al. Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). Int Clin Psychopharmacol 1997; 12: 19-29
2. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349: 1498-504
3. Simon GE. Social and economic burden of mood disorders. Biol Psychiatry 2003; 54: 208-15
4. Donoghue J, Hylan TR. Antidepressant use in clinical practice: efficacy vs effectiveness. Br J Psychiatry 2001; Suppl. 42: S9-17
5. Simon GE. Evidence review: efficacy and effectiveness of antidepressant treatment in primary care. Gen Hosp Psychiatry 2002; 24: 213-24
6. Pampallona S, Bollini P, Tibaldi G, et al. Patient adherence in the treatment of depression. Br J Psychiatry 2002; 180: 104-9
7. Katon W, Von Korff M, Lin E, et al. Collaborative management to achieve treatment guidelines: impact on depression in primary care. J Am Med Assoc 1995; 273: 1026-31
8. Katon W, Robinson P, Von Korff M, et al. A multifaceted intervention to improve treatment of depression in primary care. Arch Gen Psychiatry 1996; 53: 924-32
9. Katon W, Von Korff M, Lin E, et al. Stepped collaborative care for primary care patients with persistent symptoms of depression: a randomized trial. Arch Gen Psychiatry 1999; 56: 1109-15
10. Peveler R, George C, Kinmonth AL, et al. Effect of antidepressant drug counselling and information leaflets on adherence to drug treatment in primary care: randomised controlled trial. BMJ 1999; 319: 612-5
11. Knoell DL, Pierson JF, Marsh CB, et al. Measurement of outcomes in adults receiving pharmaceutical care in a comprehensive asthma outpatient clinic. Pharmacotherapy 1998; 18: 1365-74
12. Mehos BM, Saseen JJ, MacLaughlin EJ. Effect of pharmacist intervention and initiation of home blood pressure monitoring in patients with uncontrolled hypertension. Pharmacotherapy 2000; 20: 1384-9
13. Tsuyuki RT, Johnson JA, Teo KK, et al. A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). Arch Intern Med 2002; 162: 1149-55
14. Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med 1998; 158: 1641-7
15. Capoccia KL, Boudreau DM, Blough DK, et al. Randomized trial of pharmacist interventions to improve depression care and outcomes in primary care. Am J Health Syst Pharm 2004; 61: 364-72
16. Finley PR, Rens HR, Pont JT, et al. Impact of a collaborative pharmacy practice model on the treatment of depression in primary care. Am J Health Syst Pharm 2002; 59: 1518-26
17. Adler DA, Bungay KM, Wilson IB, et al. The impact of a pharmacist intervention on 6-month outcomes in depressed primary care patients. Gen Hosp Psychiatry 2004; 26: 199-209
18. van Marwijk HWJ, Grundmeijer HGLM, Brueren MM, et al. Guidelines on depression of the Dutch College of General Practitioners (NHG-Standaard Depressie). Huisarts Wet 1994; 37: 482-90
19. Brook O, van Hout H, Nieuwenhuyse H, et al. Impact of coaching by community pharmacists on drug attitude of depressive primary care patients and acceptability to patients; a randomized controlled trial. Eur Neuropsychopharmacol 2003; 13: 1-9
20. Brook OH, van Hout H, Stalman W, et al. A pharmacy-based coaching program to improve adherence to antidepressant treatment among primary care patients. Psychiatr Serv 2005; 56: 487-9
21. Lin EH, Von Korff M, Katon W, et al. The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care 1995; 33: 67-74
22. Derogatis LR, Lipman RS, Rickels K, et al. The Hopkins Symptom Checklist (HSCL): a measure of primary symptom dimensions. Mod Probl Pharmacopsychiatry 1974; 7: 79-110
23. Oostenbrink JB, Koopmanschap MA, Van Rutten FFH. Handbook for cost studies, methods and guidelines for economic evaluation in health care [in Dutch]. The Hague, The Netherlands: Health Care Insurance Council, 2000
24. Oostenbrink JB, Koopmanschap MA, Rutten FF. Standardisation of costs: the Dutch manual for costing in economic evaluations. Pharmacoeconomics 2002; 20: 443-54
25. Z-index. G-Standaard. The Hague, The Netherlands: Z-Index, 2002
26. Statistics Netherlands (Centraal Bureau voor Statistiek). Statline [online]. Available from URL: http://statline.cbs.nl/ [Accessed 2006 Oct 18]
27. Koopmanschap MA, Rutten FF, van Ineveld BM, et al. The friction cost method for measuring indirect costs of disease. J Health Econ 1995; 14: 171-89
28. Efron B, Tibshirani RJ. An introduction to the bootstrap. New York: Chapman & Hall, 1993
29. Chaudhary MA, Stearns SC. Estimating confidence intervals for cost-effectiveness ratios: an example from a randomized trial. Stat Med 1996; 15: 1447-58
30. Black WC. The CE plane: a graphic representation of cost-effectiveness. Med Decis Making 1990; 10: 212-4
31. Van Hout BA, Al MJ, Gordon GS, et al. Costs, effects and C/E-ratios alongside a clinical trial. Health Econ 1994; 3: 309-19
32. Briggs AH, Gray AM. Handling uncertainty in economic evaluations of healthcare interventions. BMJ 1999; 319: 635-8
33. Simon GE, Katon WJ, Von Korff M, et al. Cost-effectiveness of a collaborative care program for primary care patients with persistent depression. Am J Psychiatry 2001; 158: 1638-44
34. Von Korff M, Katon W, Bush T, et al. Treatment costs, cost offset, and cost-effectiveness of collaborative management of depression. Psychosom Med 1998; 60: 143-9
35. George CF, Peveler RC, Heiliger S, et al. Compliance with tricyclic antidepressants: the value of four different methods of assessment. Br J Clin Pharmacol 2000; 50: 166-71
36. Demyttenaere K, Van Ganse E, Gregoire J, et al. Compliance in depressed patients treated with fluoxetine or amitriptyline: Belgian Compliance Study Group. Int Clin Psychopharmacol 1998; 13: 11-7
37. Thompson C, Peveler RC, Stephenson D, et al. Compliance with antidepressant medication in the treatment of major depressive disorder in primary care: a randomized comparison of fluoxetine and a tricyclic antidepressant. Am J Psychiatry 2000; 157: 338-43
38. Simon GE, Manning WG, Katzelnick DJ, et al. Cost-effectiveness of systematic depression treatment for high utilizers of general medical care. Arch Gen Psychiatry 2001; 58: 181-7
39. Bower P, Byford S, Sibbald B, et al. Randomised controlled trial of non-directive counselling, cognitive-behaviour therapy, and usual general practitioner care for patients with depression: II. Cost effectiveness. BMJ 2000; 321: 1389-92
40. Briggs A. Economic evaluation and clinical trials: size matters. BMJ 2000; 321: 1362-3
41. Briggs A, Clark T, Wolstenholme J, et al. Missing... presumed at random: cost-analysis of incomplete data. Health Econ 2003; 12: 377-92
42. Oostenbrink JB, Al MJ. The analysis of incomplete cost data due to dropout. Health Econ 2005; 14: 763-76